---
title: "LLY, JNJ, PFE: Big Pharma's 2025 Comeback Is Bigger Than the Obesity Craze"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/271881560.md"
description: "In 2025, Big Pharma's performance was highlighted by the obesity-drug market, but overall gains were driven by broader factors. The NYSE Arca Pharmaceutical Index rose 21%, outperforming the S&P 500's 17.9% gain. Key indices like the Dow Jones U.S. Pharmaceuticals Index and S&P Pharmaceuticals Select Industry Index saw increases of 31% and 30%, respectively. Johnson & Johnson led the growth with a 43% stock increase, followed by Novartis and AstraZeneca, each over 40%. Eli Lilly also performed well, ending the year 39% stronger and entering the $1-trillion club."
datetime: "2026-01-08T05:30:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271881560.md)
  - [en](https://longbridge.com/en/news/271881560.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271881560.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/271881560.md) | [繁體中文](https://longbridge.com/zh-HK/news/271881560.md)


# LLY, JNJ, PFE: Big Pharma's 2025 Comeback Is Bigger Than the Obesity Craze

The race for obesity-drug market share was one key highlight for Big Pharma in 2025. However, data indicate that Big Pharma's 2025 rally is not solely the result of the weight-loss drug battle, as pharma indices outperformed the broader S&P 500 index in a year marked by artificial intelligence hype.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Last year, the NYSE Arca Pharmaceutical Index — which houses some of the largest pharma companies such as Eli Lilly (LLY), Johnson & Johnson (JNJ), Merck (MRK), and Pfizer (PFE) — rose about 21%, comfortably beating the S&P 500, which saw a 17.9% gain, and matching the tech-heavy Nasdaq 100 index, which grew 21%.

## **Johnson & Johnson Leads Stock Growth in 2025**

Furthermore, broader pharmaceutical indices delivered larger gains, even as President Donald Trump's drug pricing deals helped alleviate uncertainty about tariffs on the sector, thereby accelerating pharma stocks in the latter half of the year. Specifically, these indices rose:

-   Dow Jones U.S. Pharmaceuticals Index — jumped about 31%
-   S&P Pharmaceuticals Select Industry Index — rose about 30%
-   Nasdaq U.S. Smart Pharmaceuticals Index — climbed about 24%

Narrowing it down, Johnson & Johnson (JNJ) led the Big Pharma group's growth, with its stock adding 43% in 2025. This was followed by Novartis (NVS) and AstraZeneca (AZN), each with gains of more than 40%. This shows the growth story is beyond the pharma companies driving the obesity craze, although Eli Lilly (LLY) ended the year 39% stronger and joined the $1-trillion club in the same year.

### 相关股票

- [Eli Lilly (LLY.US)](https://longbridge.com/zh-CN/quote/LLY.US.md)
- [Johnson & Johnson (JNJ.US)](https://longbridge.com/zh-CN/quote/JNJ.US.md)

## 相关资讯与研究

- [Eli Lilly pushes for NHS drug price increases in return for its UK investment, FT reports](https://longbridge.com/zh-CN/news/280952509.md)
- [Eli Lilly: Foundayo will be available with prescriptions accepted immediately and shipping from April 6](https://longbridge.com/zh-CN/news/281395595.md)
- [Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | LLY Stock News](https://longbridge.com/zh-CN/news/281171668.md)
- [Lilly To Acquire Centessa; Upfront Consideration Represents Equity Value Of Approx. $6.3 Bln](https://longbridge.com/zh-CN/news/281174134.md)
- [Daratumumab becomes first oncology injectable approved for patient administration](https://longbridge.com/zh-CN/news/280990101.md)